AbL Diagnostics SA (ABLD) - Total Liabilities
Based on the latest financial reports, AbL Diagnostics SA (ABLD) has total liabilities worth €5.32 Million EUR (≈ $6.22 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of AbL Diagnostics SA to track the company's year-over-year net asset growth rate.
AbL Diagnostics SA - Total Liabilities Trend (2007–2025)
This chart illustrates how AbL Diagnostics SA's total liabilities have evolved over time, based on quarterly financial data. See AbL Diagnostics SA free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
AbL Diagnostics SA Competitors by Total Liabilities
The table below lists competitors of AbL Diagnostics SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Farm Price Holdings Berhad
KLSE:0304
|
Malaysia | RM19.85 Million |
|
Massimo Group Common Stock
NASDAQ:MAMO
|
USA | $27.72 Million |
|
NOCTILUCA S.A. ZY -15
F:G0Z
|
Germany | €1.55 Million |
|
WT Financial Group Ltd
AU:WTL
|
Australia | AU$26.32 Million |
|
Casing Macron Technology Co Ltd
TWO:3325
|
Taiwan | NT$1.02 Billion |
|
Wisher Industrial Co Ltd
TW:1465
|
Taiwan | NT$175.85 Million |
|
Sprint Bioscience AB
ST:SPRINT
|
Sweden | Skr12.69 Million |
|
Zegona Communications Plc
LSE:ZEG
|
UK | GBX6.41 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down AbL Diagnostics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of AbL Diagnostics SA.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AbL Diagnostics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AbL Diagnostics SA (2007–2025)
The table below shows the annual total liabilities of AbL Diagnostics SA from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €5.32 Million ≈ $6.22 Million |
+23.11% |
| 2024-12-31 | €4.32 Million ≈ $5.05 Million |
-46.86% |
| 2023-12-31 | €8.14 Million ≈ $9.51 Million |
-5.99% |
| 2022-12-31 | €8.65 Million ≈ $10.12 Million |
+9081.14% |
| 2021-12-31 | €94.26K ≈ $110.20K |
+420.78% |
| 2020-12-31 | €18.10K ≈ $21.16K |
-84.70% |
| 2019-12-31 | €118.31K ≈ $138.32K |
-80.07% |
| 2018-12-31 | €593.64K ≈ $694.03K |
+346.04% |
| 2017-12-31 | €133.09K ≈ $155.60K |
-17.93% |
| 2016-12-31 | €162.18K ≈ $189.60K |
-79.83% |
| 2015-12-31 | €804.11K ≈ $940.09K |
+460.64% |
| 2014-12-31 | €143.43K ≈ $167.68K |
-34.43% |
| 2013-12-31 | €218.75K ≈ $255.74K |
+151.83% |
| 2012-12-31 | €86.86K ≈ $101.55K |
-21.84% |
| 2011-12-31 | €111.14K ≈ $129.94K |
+2.38% |
| 2010-12-31 | €108.56K ≈ $126.91K |
+90.10% |
| 2009-12-31 | €57.10K ≈ $66.76K |
+12.32% |
| 2008-12-31 | €50.84K ≈ $59.44K |
-1.20% |
| 2007-12-31 | €51.46K ≈ $60.16K |
-- |
About AbL Diagnostics SA
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S… Read more